TP53-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes by Treatment Modality: A Multicenter Cohort From 14 US Centers.
Multiple treatment approaches work comparably well for aggressive lymphoma, giving patients more options tailored to their situation.
Advances in the treatment of large B-cell lymphoma (LBCL) have expanded therapeutic options beyond conventional chemoimmunotherapy to include cellular and targeted therapies. In the second and third-line setting, outcomes did not significantly differ between different treatment approaches, though improved PFS was seen with CAR-T in the second line for double hit patients.
What the study was
- Study design
- Cohort study
- Population
- patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- European journal of haematology
Why it surfaced
Score 7/10 [NOVEL_TREATMENT]: Cohort study (Journal Article) matched 'Hematologic malignancies'. Components — novelty:2/3, relevance:2/3, design:1/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.